LDV/SOF FDC

DRUG2 trials

Sponsors

HepNet Study House, German Liverfoundation, Peter J. Ruane, M.D., Inc.

Conditions

Acute Hepatitis CChronic Hepatitis C

Phase 2

HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection

CompletedNCT02309918

HepNet Study House, German LiverfoundationAcute Hepatitis C

Start: 2014-11-30End: 2016-08-31Updated: 2017-08-28

Phase 4

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Peter J. Ruane, M.D., Inc.Chronic Hepatitis C

Start: 2016-02-29End: 2017-05-31Target: 40Updated: 2016-02-25

Related Papers

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

2016-10-2881 citations